Medgex
ActiveSummary
Medgex has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €79,997 and a net result of €24,555. Equity is growing by ~27.8% per year across the filed fiscal years. Its solvency ranks better than 19% of 16754 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability76▼-8
Solvency45▼-38
Growth78=
Track record94
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €5,000 at 30 days acceptable
Liquidity tight (current ratio 1.45 against 2.81 in 2024; short-term debt: 31.1% and cash: 13.9% of total assets), and 80.4% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Human health activities (NACE 86)
about 87% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
19.6%
Return on assets
6%
Age of the figures
9 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 19% of 16754 sector peers (2025).
NBB · sector comparisonPosition among 16754 sector peers
Solvency
better than 19%
← weakest
strongest →
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 21-08-2026, 21 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 4 filingsDeviation from the deadline
2025
21 d late
2024
14 d early
2023
35 d early
2022
28 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 4 accounts on average on the deadline day; the sector median for financial year 2024 is 7 days before the deadline, and 36% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 4 August (3 of the last 4 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
28-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, micro schema
Equity
€79,997=
2024 · €79,997
Total assets
€408,387▲ 196%
2024 · €137,866
Net result
€24,555▲ 48.0%
2024 · €16,593
Working capital
€57,689▼ 11.5%
2024 · €65,158
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line2022202320242025
Operating result€6,013-€75,297▲ 1,152%€26,546▼ 64.7%€34,481▲ 29.9%
Net result€4,169below the sector's middle half-€53,234within the sector's middle half▲ 1,177%€16,593below the sector's middle half▼ 68.8%€24,555within the sector's middle half▲ 48.0%
Equity€10,169below the sector's middle half-€63,404within the sector's middle half▲ 523%€79,997within the sector's middle half▲ 26.2%€79,997within the sector's middle half=
Total assets€22,934below the sector's middle half-€169,779within the sector's middle half▲ 640%€137,866within the sector's middle half▼ 18.8%€408,387within the sector's middle half▲ 196%
Debt€12,764-€106,375▲ 733%€57,870▼ 45.6%€328,390▲ 467%
Working capital-€2,491below the sector's middle half-€44,724within the sector's middle half€65,158within the sector's middle half▲ 45.7%€57,689within the sector's middle half▼ 11.5%
Solvency44.3%within the sector's middle half-37.3%within the sector's middle half▼ 7.0pp58.0%within the sector's middle half▲ 20.7pp19.6%below the sector's middle half▼ 38.4pp
Current ratio0.80below the sector's middle half-1.62within the sector's middle half▲ 0.812.81within the sector's middle half▲ 1.191.45within the sector's middle half▼ 1.35
Return on assets (ROA)18.2%within the sector's middle half-31.4%within the sector's middle half▲ 13.2pp12.0%within the sector's middle half▼ 19.3pp6.0%below the sector's middle half▼ 6.0pp
above
within
below
the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 30% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €408,387
Fixed assets
€223,633 ▲ 511%
Current assets
€184,754 ▲ 82.5%
Equity and liabilities €408,387
Equity
€79,997 =
Debt
€328,390 ▲ 467%
Debt's share of the balance-sheet total rises from 42.0% to 80.4%. Debt is higher.
Key figures and ratios
EBITDA
€72,837▲
2024 · €38,975
Cash flow
€62,912▲
2024 · €29,022
Debt to equity
4.11▲
2024 · 0.72
ROE
30.7%▲
2024 · 20.7%
Interest coverage
21.78▲
2024 · 12.37
Debt ≤ 1 year
€127,065▲
2024 · €36,093
Debt > 1 year
€201,247▲
2024 · €21,776
Income taxes
€6,581▼
2024 · €6,802
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 7,976 companies that looked in July 2024 the way this one looks now, 3.1% went bankrupt within 24 months and 94% are still going.
- Micro
- 2 to 5 years old
- solvency 10 to 30%
- a profit of 5% of the balance sheet or more
3.1%
went bankrupt
1.6%
stopped otherwise
94%
still going
A further 1.0% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.3% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,662 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.7% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 75% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 7,976 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | €114 | - | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €365 | €3,087 | €12,429 | €38,356 | ▲ 209% |
| Other operating charges640/8 | €191 | €1,768 | €1,118 | €1,504 | ▲ 34.6% |
| Gross operating margin9900 | €6,569 | €80,152 | €40,093 | €74,341 | ▲ 85.4% |
| Operating profit (loss)9901 | €6,013 | €75,297 | €26,546 | €34,481 | ▲ 29.9% |
| Financial income75/76B | - | - | €0 | - | - |
| Recurring financial income75 | - | - | €0 | - | - |
| Financial charges65/66B | €193 | €1,543 | €3,151 | €3,345 | ▲ 6.1% |
| Recurring financial charges65 | €193 | €1,543 | €3,151 | €3,345 | ▲ 6.1% |
| Profit (loss) for the period before taxes9903 | €5,820 | €73,754 | €23,395 | €31,136 | ▲ 33.1% |
| Income taxes67/77 | €1,650 | €20,520 | €6,802 | €6,581 | ▼ 3.3% |
| Profit (loss) for the period9904 | €4,169 | €53,234 | €16,593 | €24,555 | ▲ 48.0% |
| Profit (loss) for the period to be appropriated9905 | €4,169 | €53,234 | €16,593 | €24,555 | ▲ 48.0% |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Assets | |||||
| Total assets20/58 | €22,934 | €169,779 | €137,866 | €408,387 | ▲ 196% |
| Fixed assets21/28 | €12,660 | €52,744 | €36,615 | €223,633 | ▲ 511% |
| Tangible fixed assets22/27 | €12,660 | €52,744 | €36,615 | €223,633 | ▲ 511% |
| Land and buildings22 | - | - | - | €194,575 | - |
| Plant, machinery and equipment23 | €2,392 | €2,150 | €1,908 | €1,666 | ▼ 12.7% |
| Furniture and vehicles24 | €10,268 | €50,594 | €34,707 | €27,393 | ▼ 21.1% |
| Current assets29/58 | €10,273 | €117,035 | €101,251 | €184,754 | ▲ 82.5% |
| Amounts receivable within one year40/41 | €3,049 | €46,687 | €15,686 | €124,788 | ▲ 696% |
| Trade receivables40 | €3,049 | €46,687 | €465 | €83,963 | ▲ 17,954% |
| Other amounts receivable41 | - | - | €15,221 | €40,825 | ▲ 168% |
| Cash at bank and in hand54/58 | €5,040 | €70,200 | €82,938 | €56,926 | ▼ 31.4% |
| Deferred charges and accrued income490/1 | €2,184 | €148 | €2,628 | €3,040 | ▲ 15.7% |
| Equity and liabilities | |||||
| Total equity and liabilities10/49 | €22,934 | €169,779 | €137,866 | €408,387 | ▲ 196% |
| Equity10/15 | €10,169 | €63,404 | €79,997 | €79,997 | = |
| Contributions10/11 | €6,000 | €6,000 | €6,000 | €6,000 | = |
| Reserves13 | €4,169 | €57,404 | €73,997 | €73,997 | = |
| Distributable reserves133 | €4,169 | €57,404 | €73,997 | €73,997 | = |
| Amounts payable17/49 | €12,764 | €106,375 | €57,870 | €328,390 | ▲ 467% |
| Amounts payable after more than one year17 | - | €34,000 | €21,776 | €201,247 | ▲ 824% |
| Financial debts170/4 | - | €34,000 | €21,776 | €201,247 | ▲ 824% |
| Amounts payable within one year42/48 | €12,764 | €72,311 | €36,093 | €127,065 | ▲ 252% |
| Current portion of amounts payable after more than one year42 | - | €8,000 | €10,300 | €19,565 | ▲ 89.9% |
| Trade debts44 | €1,341 | €46,838 | €2,541 | €66,774 | ▲ 2,528% |
| Suppliers440/4 | €1,341 | €46,838 | €2,541 | €66,774 | ▲ 2,528% |
| Taxes, remuneration and social security45 | €10,817 | €17,250 | €20,079 | €7,653 | ▼ 61.9% |
| Taxes450/3 | €5,317 | €17,250 | €7,079 | €7,653 | ▲ 8.1% |
| Remuneration and social security454/9 | €5,500 | - | €13,000 | - | - |
| Other amounts payable47/48 | €607 | €223 | €3,172 | €33,073 | ▲ 942% |
| Accrued charges and deferred income492/3 | - | €64 | - | €79 | - |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €4,169 | €53,234 | €16,593 | €24,555 | ▲ 48.0% |
| + Depreciation and write-downs630 | €365 | €3,087 | €12,429 | €38,356 | ▲ 209% |
| Operating cash flow (approximation) | €4,535 | €56,322 | €29,022 | €62,912 | ▲ 117% |
| Investment in fixed assets (approximation) | - | -€43,171 | €3,700 | -€225,374 | ▼ 6,192% |
| Change in cash | - | €65,159 | €12,738 | -€26,012 | ▼ 304% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
21-08
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 21 days late
2025
17-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
26-06
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Highest result since 2022net €53,234 ▲1,177%
Operating result €75,297, net result €53,234, both a record.
31-12
Financial
Liquidity doublescurrent ratio 1.62
Current ratio from 0.80 to 1.62.
28-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 28 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 1 act read
About the unread acts
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Sint-Lambrechts-Woluwe · 1 establishment unit since 2022
Ground area
387 m²
Building footprint
259 m²
Volume, LiDAR
4,015 m³
Parcel 21672C0281/00X004, Brussels · tallest building 18.4 m, ±5 floors. Linked by address, not a title deed.
7
companies at this address
See who is registered here
1 establishment unit
MEDGEX
since 20222.347.490.862
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21672C0281/00X004 | Brussels | 387 m² | 1 · 259 m² | 18.4 m · 5 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
AXIS
BE 0898.340.952
Wuustwezel · Eq €79,980
DR. ELISE VEYS
BE 1000.563.710
Gent · Eq €79,975
Dokter Nathalie Saeys
BE 0701.969.402
Lier · Eq €80,019
smart santé
BE 0835.614.715
Gerpinnes · Eq €79,930
DR. KATRIEN VAN HOEYMISSEN
BE 0760.439.913
Bilzen-Hoeselt · Eq €80,083
Of 9,128 companies in sector 86210 we hold annual accounts for 6,335. 5,091 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded15-11-2022
Fiscal year end31-12
Activities, NACEBEL 2025
86210General medical practice
86220Specialist medical practice
Contact
E-mail
luciedvdg@gmail.com
Phone
+32470626433
E-invoicing
Reachable via Peppol
Peppol ID
0208:0793602332
Also
9925:BE0793602332
Registered
08-12-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 28 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.